Alpana Naresh, PhD, joined Hinge Bio in March 2025. She was most recently the Executive Director of CMC Operations at Harpoon Therapeutics, Inc and subsequently Merck, following Merck’s acquisition of Harpoon. At Harpoon, Alpana worked on the development, transfer, and manufacturing of novel T-cell engager molecules (Tri-specific T cell Activating Construct (TriTAC®) platform and ProTriTAC™ platform) for clinical studies of various cancers.  She was responsible for CMC operations for clinical supply including regulatory filing and CMC strategy for multiple molecules while at Harpoon. Previous positions included roles at Boehringer Ingelheim, JSR Life Sciences, Sutro Biopharma, Genitope, and post-doctoral fellowships at Stanford University and University of Virginia. Dr. Naresh is a collaborative, results driven biotechnology professional with more than 25 years of research and development experience with multiple biomolecules including immunoglobulins as personalized vaccines for cancer, monoclonal antibodies, bispecific antibodies, and trispecific antibody-derived modalities. Dr. Naresh received her Masters in Biotechnology from CCSHAU and Doctor of Philosophy in Biotechnology from IMTech, Chandigarh and was post-doctoral fellow at Stanford University in Professor Cleary’s lab.